Edition:
United States

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.77USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
24,835
52-wk High
$11.26
52-wk Low
$4.03

Latest Key Developments (Source: Significant Developments)

Foamix Q2 loss per share $0.44
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Foamix Pharmaceuticals Ltd :Foamix reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.44.Q2 revenue $798,000 versus $752,000.Foamix pharmaceuticals - ‍"currently well-capitalized", have sufficient cash to fund key development programs (FMX101 and FMX103) until mid-2019​.  Full Article

Foamix says expects to report top-line results from study FX2017-22 by mid-2018​
Thursday, 3 Aug 2017 08:00am EDT 

Aug 3 (Reuters) - Foamix Pharmaceuticals Ltd :Foamix announces dosing of first patient in third phase 3 acne study for minocycline foam fmx101.Foamix pharmaceuticals ltd- ‍foamix expects to report top-line results from study fx2017-22 by mid-2018​.Foamix pharmaceuticals - ‍as result of fda discussion on design of third study, co decided to maintain design agreed upon with fda for study fx2014-05​.  Full Article

Foamix Pharmaceuticals appoints David Domzalski as CEO
Thursday, 29 Jun 2017 08:00am EDT 

June 29 (Reuters) - Foamix Pharmaceuticals Ltd ::Foamix Pharmaceuticals appoints David Domzalski as chief executive officer.Foamix Pharmaceuticals Ltd - Domzalski succeeds Dov Tamarkin as CEO.Foamix Pharmaceuticals Ltd - Tamarkin will continue to be a member of company's Board of directors and will serve as chief scientific advisor to Foamix.Foamix Pharmaceuticals Ltd - Ilan Hadar, current CFO of Foamix, will assume role of country manager in Israel, in addition to his role as CFO.  Full Article

Foamix announces dosing of first patient in phase 3 rosacea clinical trials
Monday, 12 Jun 2017 08:00am EDT 

June 12 (Reuters) - Foamix Pharmaceuticals Ltd :Foamix announces dosing of first patient in phase 3 rosacea clinical trials for FMX103 minocycline foam 1.5%.Foamix Pharmaceuticals Ltd - "we expect topline data in mid-2018".  Full Article

Foamix Pharmaceuticals reports Q1 2017 financial results
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Foamix Pharmaceuticals Ltd ::Foamix reports first quarter 2017 financial results and provides business update.Q1 loss per share $0.39.Q1 revenue $927,000 versus $745,000.Says as of march 31, 2017, we had cash and investments of $118.7 million, compared with $131.0 million as of december 31, 2016.  Full Article

Foamix Pharmaceuticals announces plans for additional phase 3 trial for FMX101 in moderate to severe acne
Monday, 1 May 2017 04:05pm EDT 

May 1 (Reuters) - Foamix Pharmaceuticals Ltd ::Foamix Pharmaceuticals announces plans for additional phase 3 trial for fmx101 in moderate to severe acne.Foamix Pharmaceuticals ltd- commencement of 3(rd) phase 3 trial planned mid 2017; submittal of nda planned in h2-2018.Foamix pharmaceuticals announces plans for additional phase 3 trial for fmx101 in moderate to severe acne.Foamix pharmaceuticals ltd- pooled analyses of phase 3 data show additional statistically significant effects on primary and secondary efficacy endpoints.Foamix pharmaceuticals - if results will be positive, trial is expected to form basis for a nda which company plans to submit in second half of 2018.  Full Article

Foamix reports topline results from phase 3 trials for fmx101
Monday, 27 Mar 2017 07:30am EDT 

Foamix Pharmaceuticals Ltd : Foamix reports topline results from phase 3 trials for fmx101 in patients with acne . Foamix Pharmaceuticals - in intent-to-treat analysis, FMX101 demonstrated statistical significance compared to vehicle on both co-primary endpoints in trial 05 . Foamix - in intent-to-treat analysis, FMX101 did not demonstrate statistical significance on one of two co-primary endpoints in trial 04 .Foamix Pharmaceuticals Ltd - FMX101 was generally safe and well-tolerated.  Full Article

Foamix Pharmaceuticals may offer its ordinary shares of up to $291.9 mln
Friday, 24 Feb 2017 04:10pm EST 

Foamix Pharmaceuticals Ltd :Says it may offer its ordinary shares of up to $291.9 million.  Full Article

Foamix reports year end 2016 financial results and provides business update
Wednesday, 22 Feb 2017 08:00am EST 

Foamix Pharmaceuticals Ltd : Foamix reports year end 2016 financial results and provides business update .Foamix Pharmaceuticals - estimates existing cash, investments provide sufficient financial flexibility to finance clinical, business operations into 2019.  Full Article

Foamix Q3 loss per share $0.19
Tuesday, 15 Nov 2016 04:15pm EST 

Foamix Pharmaceuticals Ltd : Foamix Pharmaceuticals - as of Sept 30, cash, cash equivalents, short and long-term investments of $140.1 million, compared with $103.8 million as of Dec 31, 2015 . Q3 loss per share $0.19 . Foamix reports third quarter 2016 financial results and provides business update .Q3 revenue $2.5 million.  Full Article

BRIEF-Foamix Q3 loss per share $0.47

* Foamix reports third quarter 2017 financial results and provides business update